Prediction of the varices needing treatment with non‐invasive tests in patients with compensated advanced chronic liver disease

2019 ◽  
Vol 39 (6) ◽  
pp. 1071-1079 ◽  
Author(s):  
Han Ah Lee ◽  
Seung Up Kim ◽  
Yeon Seok Seo ◽  
Young‐Sun Lee ◽  
Seong Hee Kang ◽  
...  
Keyword(s):  
Liver Disease ◽  
Chronic Liver Disease ◽  
Chronic Liver ◽  
Non Invasive

Mac‐2 Binding Protein Glycan Isomer as non‐invasive tool to assess liver fibrosis in children with chronic liver disease

2021 ◽  
Author(s):  
Ola G Behairy ◽  
Soha A El‐Gendy ◽  
Dalia Y Ibrahim ◽  
Amira I Mansour ◽  
Ola S El‐Shimi
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Chronic Liver Disease ◽  
Binding Protein ◽  
Chronic Liver ◽  
Non Invasive

scholarly journals A72 NON-INVASIVE PREDICTION OF ESOPHAGEAL VARICES BY TRANSIENT ELASTOGRAPHY AND PLATELET COUNT IN PATIENTS WITH HEPATITIS B AND ADVANCED CHRONIC LIVER DISEASE: VALIDATION OF BAVENO VI AND EXPANDED BAVENO VI CRITERIA

2021 ◽  
Vol 4 (Supplement_1) ◽  
pp. 37-38
Author(s):  
A Zoughlami ◽  
J Serero ◽  
G Sebastiani ◽  
M Deschenes ◽  
P Wong ◽  
...  
Keyword(s):  
Platelet Count ◽  
Liver Disease ◽  
Hepatitis B ◽  
Chronic Liver Disease ◽  
Esophageal Varices ◽  
Diagnostic Performance ◽  
Transient Elastography ◽  
Chronic Liver ◽  
Non Invasive ◽  
Chronic Hepatitis B Virus

Abstract Background Patients with compensated advanced chronic liver disease (cACLD) are at higher risk of developing complications from portal hypertension, including esophageal varices (EV). Baveno VI and expanded Baveno VI criteria, based on liver stiffness measurement (LSM) by transient elastography combined with platelet count, have been proposed to avoid unnecessary esophagogastroduodenoscopy (EGD) screening for large esophageal varices needing treatment (EVNT). This approach has not been validated in patients with chronic hepatitis B virus (HBV) infection, who have etiology-specific cut-off of LSM for liver fibrosis. Aims We aimed to validate the Baveno VI and expanded Baveno VI criteria for EVNT in HBV patients with cACLD. Methods We performed a retrospective analysis of HBV patients who underwent LSM in 2014–2020. Inclusion criteria were: a) diagnosis of cACLD, defined as LSM >9 kPa; b) availability of EGD and platelets within 1 year of LSM. Baveno VI (LSM <20 kPa and platelets >150,000) and expanded Baveno VI criteria (LSM <25 kPa and platelets >110,000) were tested for EGD sparing. Diagnostic performance of these criteria against gold standard (EGD) was computed and compared to patients with hepatitis C virus (HCV) infection and nonalcoholic steatohepatitis (NASH) etiologies, where these criteria have been widely validated. In these patients, the threshold for cACLD definition was >10 kPa. Results A total of 287 patients (mean age 56, 95% Child A) were included, comprising of 43 HBV (58% on antiviral therapy), 134 HCV and 110 NASH patients. The prevalence of any grade EV and EVNT was 25% and 8% in the whole cohort, with 19% and 5% in HBV patients, respectively. Table 1 reports diagnostic performance, spared EGD and missed EVNT according to non-invasive criteria and cACLD etiology. Both Baveno VI and expanded Baveno VI criteria performed well in patients with HBV-related cACLD. There was no significant difference on diagnostic performance of these non-invasive criteria across the cACLD etiologies. Conclusions These results support use of non-invasive criteria based on LSM and platelets to spare unnecessary EGD in patients with HBV and cACLD. Baveno VI and expanded Baveno VI criteria can improve resource utilization and avoid invasive testing in context of screening EGD for patients with HBV-related cACLD. Funding Agencies None

scholarly journals P16 Non-invasive evaluation of fibrosis in paediatric chronic liver disease

Gut ◽  
2011 ◽  
Vol 60 (Suppl 2) ◽  
pp. A8-A8
Author(s):  
E. Fitzpatrick ◽  
M.-S. Basso ◽  
A. Quaglia ◽  
R. R. Mitry ◽  
A. Dhawan
Keyword(s):  
Liver Disease ◽  
Chronic Liver Disease ◽  
Chronic Liver ◽  
Non Invasive ◽  
Invasive Evaluation

scholarly journals Non-invasive markers of liver fibrosis in chronic liver disease in a group of Mexican children. A multicenter study

2012 ◽  
Vol 11 (3) ◽  
pp. 364-368 ◽  
Author(s):  
Judith Flores-Calderón ◽  
Segundo Morán-Villota ◽  
Guillermo Ramón-García ◽  
Berenice González-Romano ◽  
María del Carmen Bojórquez-Ramos ◽  
...  
Keyword(s):  
Liver Disease ◽  
Liver Fibrosis ◽  
Chronic Liver Disease ◽  
Multicenter Study ◽  
Chronic Liver ◽  
Non Invasive ◽  
Mexican Children

scholarly journals Non-invasive monitoring of chronic liver disease via near-infrared and shortwave-infrared imaging of endogenous lipofuscin

2020 ◽  
Vol 4 (8) ◽  
pp. 801-813 ◽  
Author(s):  
Mari Saif ◽  
Wilhelmus J. Kwanten ◽  
Jessica A. Carr ◽  
Ivy X. Chen ◽  
Jessica M. Posada ◽  
...  
Keyword(s):  
Liver Disease ◽  
Chronic Liver Disease ◽  
Near Infrared ◽  
Infrared Imaging ◽  
Chronic Liver ◽  
Invasive Monitoring ◽  
Non Invasive ◽  
Shortwave Infrared

Pathogenesis, Diagnosis and Treatment of Hemochromatosis

2016 ◽  
Vol 34 (4) ◽  
pp. 364-373 ◽  
Author(s):  
Heinz Zoller ◽  
Benjamin Henninger
Keyword(s):  
Liver Disease ◽  
Chronic Liver Disease ◽  
Transferrin Saturation ◽  
Chronic Liver ◽  
Diagnosis And Treatment ◽  
Alternative View ◽  
Hepatic Iron ◽  
Iron Storage ◽  
Non Invasive ◽  
Tissue Iron

Hemochromatosis is a common cause of chronic liver disease and HFE genotyping allows decisive and non-invasive diagnosis. Molecular and clinical genetic studies have led to the identification of genes other than HFE in patients with inherited diseases associated with increased hepatic iron storage that can cause hemochromatosis, which adds complexity to a diagnostic approach to patients with suspected hemochromatosis. Despite major advances in genetics, hepatic iron quantification by non-invasive methods therefore remains the key to the diagnosis of hemochromatosis. Although associated with homozygosity for the C282Y polymorphism in the HFE gene in >80% of patients, hemochromatosis is a complex genetic disease with strong environmental disease modifiers. Testing for mutations in the non-HFE hemochromatosis genes transferrin receptor 2, hemojuvelin, HAMP and SLC40A1 is complex, costly and time-consuming. Demonstration of hepatic iron overload by liver biopsy or MRI is therefore required before such complex tests are carried out. The pathogenesis of chronic liver disease in hemochromatosis is mainly attributed to the redox potential of tissue iron, and only the more recent studies have focused on the toxic properties of circulating iron. Considering the fact that an increased saturation of transferrin and high iron in plasma are the hallmark of all hemochromatosis forms, an alternative view would be that toxic iron in the circulation is involved in the pathogenesis of hemochromatosis. Recent studies have shown an increased concentration of redox-active iron in plasma in patients with increased transferrin saturation. This finding supports the hypothesis that tissue iron may be the ‘smoking gun' of iron-induced organ damage. Taken together, caring for patients with suspected or established hemochromatosis still remains a challenge, where understanding the genetics, biochemistry and cell biology of hemochromatosis will aid better diagnosis and treatment of affected individuals.

Sign in / Sign up

Export Citation Format

Share Document